• Explore /
  • Poster
  • / Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

Abstract Poster

Authors

Nadia Harbeck

Nadia Harbeck

Brustzentrum der Universität München (LMU), Munich, Germany

Nadia Harbeck , Ulrike Nitz , Matthias Christgen , Ronald E. Kates , Michael Wilhelm Braun , Sherko Kummel , Claudia Schumacher , Jochem Potenberg , Wolfram Malter , Doris Augustin , Bahriye Aktas , Helmut Forstbauer , Joke Tio , Anke Kleine-Tebbe , Cornelia Liedtke , Sanne de Haas , Regula Deurloo , Rachel Wuerstlein , Hans Heinrich Kreipe , Oleg Gluz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT01817452

Citation

J Clin Oncol 36, 2018 (suppl; abstr 572)

DOI

10.1200/JCO.2018.36.15_suppl.572

Abstract #

572

Poster Bd #

64

Abstract Disclosures

Similar Posters

First Author: Tejal Amar Patel

First Author: Ingrid A. Mayer

First Author: Sinead Toomey

First Author: Otto Metzger Filho